Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Pain 1Neoplasms 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Fatigue 1Diverticulitis 1Confusion 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × Caffeine × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡